TECHNOLOGY LICENSING OPPORTUNITY: SmartBind pH Switch
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
TRIAD - DOE CONTRACTOR
Contract Value
Not provided
Codes & Classification
Solicitation Number
S-133461
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
6550
Additional Details
Documents1
Los Alamos National Laboratory (LANL), operating as a federal contractor under TRIAD, has issued a special notice regarding a technology licensing opportunity for the innovative SmartBind pH Switch. This technology represents a significant advancement in the field of protein purification, specifically targeting the challenges associated with antibody isolation—a critical process in biopharmaceuticals, life sciences research, bioprocessing, and veterinary/agricultural biotechnology.
The SmartBind pH Switch is an engineered, pH-switchable version of Protein G, a molecule traditionally used to capture antibodies. Conventional methods require highly acidic conditions to release antibodies from Protein G, which can damage both the antibodies and the protein, leading to reduced yields and compromised effectiveness in downstream applications. The SmartBind innovation overcomes these limitations by enabling antibody release at a mild, basic pH (~8.2), as opposed to the harsh acidic conditions (~2.7) previously required. This gentle elution process preserves antibody integrity, enhances stability and yield, and reduces the need for costly post-purification repairs or replacements.
Key features of the SmartBind pH Switch include:
- Gentle elution conditions that minimize damage to sensitive proteins.
- Improved antibody stability and yield, crucial for therapeutic and diagnostic applications.
- A switchable binding mechanism utilizing pH-sensitive histidine residues, allowing precise control and reproducibility in purification processes.
- Cost-effective and scalable operation, reducing material loss and operational expenses in industrial settings.
The technology is currently at Technology Readiness Level (TRL) 4 and is protected under US Provisional Patent No. 10,954,275 (reference LA-UR-25-29451). LANL’s licensing program is designed to transition laboratory-developed inventions into commercial products, offering both exclusive and non-exclusive licensing agreements to established and start-up companies. This opportunity is not a solicitation for external development services; rather, it is an invitation for organizations to license and commercialize the SmartBind pH Switch technology.
The procurement is classified under NAICS Code 325413 (In-Vitro Diagnostic Substance Manufacturing, 2022 version) and Product Service Code 6550. There are no set-aside requirements associated with this notice. The place of performance is Los Alamos, New Mexico, United States.
Interested parties are encouraged to contact Marc Witkowski or Lindsay Augustyn at [email protected] for further information and to discuss licensing arrangements. Additional details about LANL’s technology partnerships and licensing process can be found at the following URLs:
- https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
- https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
The notice remains active, with a response deadline of December 6, 2025. Contractors and companies seeking to enhance their product portfolios with cutting-edge, scalable, and efficient antibody purification solutions are encouraged to evaluate this opportunity for alignment with their strategic objectives and capabilities.